Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

228 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study.
Niederwieser D, Lang T, Krahl R, Heinicke T, Maschmeyer G, Al-Ali HK, Schwind S, Jentzsch M, Cross M, Kahl C, Wolf HH, Sayer H, Schulze A, Dreger P, Hegenbart U, Krämer A, Junghanss C, Mügge LO, Hähling D, Hirt C, Späth C, Peter N, Opitz B, Florschütz A, Reifenrath K, Zojer N, Scholl S, Pönisch W, Heyn S, Vucinic V, Hochhaus A, Aul C, Giagounidis A, Balleisen L, Oldenkott B, Staib P, Kiehl M, Schütte W, Naumann R, Eimermacher H, Dörken B, Sauerland C, Lengfelder E, Hiddemann W, Wörmann B, Müller-Tidow C, Serve H, Schliemann C, Hehlmann R, Berdel WE, Pfirrmann M, Krug U, Hoffmann VS. Niederwieser D, et al. Among authors: maschmeyer g. Ann Hematol. 2023 Mar;102(3):547-561. doi: 10.1007/s00277-023-05087-8. Epub 2023 Jan 25. Ann Hematol. 2023. PMID: 36695874 Free PMC article.
GM-CSF in the treatment of acute myeloid leukemia.
Hiddemann W, Maschmeyer G, Ludwig WD, Königsmann M, Zühlsdorf M, Wörmann B, Boeckmann A, Agion-Freire E, Innig G, Reuter C, et al. Hiddemann W, et al. Among authors: maschmeyer g. Pathol Biol (Paris). 1992 Nov;39(9):959. Pathol Biol (Paris). 1992. PMID: 1538952 No abstract available.
High-dose versus intermediate-dose cytarabine combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age-adjusted randomized comparison.
Hiddemann W, Aul C, Maschmeyer G, Schönrock-Nabulsi R, Ludwig WD, Bartholomäus A, Bettelheim P, Becker K, Balleisen L, Lathan B, et al. Hiddemann W, et al. Among authors: maschmeyer g. Semin Hematol. 1991 Jul;28(3 Suppl 4):35-8. Semin Hematol. 1991. PMID: 1780750 Clinical Trial. No abstract available.
High-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia--preliminary clinical and pharmacological data of a randomized comparison.
Hiddemann W, Schleyer E, Uhrmeister C, Aul CH, Maschmeyer G, Heinecke A, Büchner T. Hiddemann W, et al. Among authors: maschmeyer g. Cancer Treat Rev. 1990 Sep;17(2-3):279-85. doi: 10.1016/0305-7372(90)90058-n. Cancer Treat Rev. 1990. PMID: 2272043 Clinical Trial.
Treatment of refractory Hodgkin's disease with high-dose cytosine arabinoside and mitoxantrone in combination. Results of a clinical phase II study of the German Hodgkin Study Group.
Hiddemann W, Schmitz N, Pfreundschuh M, Pflüger KH, Ollech-Chwoyka J, Tirier C, Maschmeyer G, Kirchner H, Wagner T, Koch P, et al. Hiddemann W, et al. Among authors: maschmeyer g. Cancer. 1990 Sep 1;66(5):838-43. doi: 10.1002/1097-0142(19900901)66:5<838::aid-cncr2820660504>3.0.co;2-r. Cancer. 1990. PMID: 2386912
228 results